Retrospective 3,214 veterans with cirrhosis comparing 1,607 participants taking ursodeoxycholic acid (UDCA) to 1,607 propensity score matched controls not taking UDCA. UDCA use was associated with significantly lower odds of SARS-CoV-2 infection (aOR 0.54), symptomatic COVID-19 (aOR 0.54), moderate or worse COVID-19 (aOR 0.51), and severe/critical COVID-19 (aOR 0.48). While retrospective, the results suggest UDCA may reduce COVID-19 susceptibility and severity in patients with cirrhosis through downregulation of ACE2 receptors.
|
risk of case, 46.0% lower, OR 0.54, p < 0.001, treatment 1,607, control 1,607, RR approximated with OR.
|
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
John et al., 5 Apr 2023, retrospective, USA, peer-reviewed, 15 authors.
